Johnson & Johnson's Use of Technology and Data

Use of Technology and Data
Author’s Name
The Institutional Affiliation
Course Number and Name
Instructor Name
Assignment Due Date
Use of Technology and Data
Johnson & Johnson
J&J relied heavily on data science and AI to find alternative channels and ensure timely delivery. In the case of orthopaedic companies, many have had to focus on manufacturing ventilators, face shields, and face masks, according to a recent survey of orthopaedic and spine companies by spine market research and consulting firm Kalorama Information. J&J has recently used Google Glass to improve supervisors and virtual reality solutions to improve orthopaedics training. The company understands the benefits of machine learning in understanding the demand and strengthening the services and offerings. Robotics and AI are beneficial in collecting information and improving outcomes. J&J relies on digital twinning in optimizing efficiency and strengthening output. Besides, the business has launched a skin health application allowing customers to take pictures with immediate feedback about personalization (Wyckoff, 2021). These all technologies have assisted the business in improving its market share and overcoming competition.
Moderna
The company has recently invested in mRNA Technology to fuel Moderna’s vaccine pipeline. The company has been a leading business in research & development in tackling diseases and viruses where processes were replicated repeatedly. mRNA is a technologically based treatment to prevent and treat diseases. mRNA carries instructions for the protein to fight against body infections and diseases. The business has launched new mRNA access programs where scientists can access vaccine technology worldwide (Parkinson, 2022).
The business relies on a highly competitive environment for talent to retain people in the biotechnology and pharmaceutical sector. Moderna manufactures its vaccines using mRNA technology, which allows for rapid manufacturing and delivery of vaccines to patients, according to the company’s website. mRNA technology also reduces the risk of vaccine-derived illness by up to 60%. Moderna is also working with AstraZeneca, which has a supply deal with the U.S. government (Moderna ESG Report, 2021).
AstraZeneca
NiCoLA-B Technology is a technology that helps AstraZeneca to de...